MOTS-c Regulatory Status: Category 2 Access in 2026
Where a widely discussed mitochondrial peptide actually stands with regulators.
TL;DR
MOTS-c regulatory status in 2026: this mitochondrial-derived peptide is not FDA-approved and remains classified as Category 2, so 503A pharmacies cannot compound it. An April 2026 HHS action reclassified 12 other peptides, but MOTS-c was not included. Its future depends on a formal FDA Federal Register notice that has not yet been issued.
MOTS-c regulatory status: is MOTS-c FDA approved?
MOTS-c is not FDA-approved for any use, including metabolic support or exercise performance. It was discovered inside mitochondrial DNA (in plain English: the small separate set of genetic instructions living inside a cell's energy-producing structures) and has mostly been studied in mice and small early human trials. No pharmaceutical company has taken it through the FDA approval process for a specific medical indication.
Is MOTS-c legal in 2026?
MOTS-c occupies a regulatory gray zone. Researching it is not illegal, but 503A compounding pharmacies cannot legally prepare it into an individual prescription while it holds Category 2 status (FDA, Bulk Drug Substances Nominated for Compounding). Category 2 means the FDA reviewed the compound and found the current evidence insufficient to support routine compounding, not a finding that the peptide is harmful by definition.
Why is MOTS-c still Category 2?
In April 2026, HHS ordered 12 peptides moved out of Category 2 restriction. MOTS-c was not one of them. It remains grouped with BPC-157 and TB-500 as compounds still awaiting formal FDA action through the Federal Register (Federal Register, FDA agency notices). Getting reclassified requires new evidence review, not just a policy announcement, so timing is genuinely uncertain.
Who asks about MOTS-c's regulatory status
People come to this question after reading about MOTS-c in exercise-science or longevity circles and wanting to know if a doctor can actually prescribe it. Regulatory status for Category 2 peptides has shifted multiple times in the past year, so a compound's story today may not match what a forum post from six months ago said.
The Halftime POV
We would rather say "not yet available through compounding" plainly than let a reader assume access exists because a peptide is popular online. MOTS-c's science is genuinely interesting. Its regulatory status is genuinely unresolved. We track FDA and HHS notices closely so our guidance reflects where things stand today, not where they might land eventually.
Related reading:
- MOTS-c: The Mitochondria-Derived Peptide Explained
- Who Asks About MOTS-c and What They Want to Understand
- Why Some Peptides Are Still Category 2
- Category 1 vs Category 2 Explained
FAQ
Is MOTS-c FDA approved? No. MOTS-c is not FDA-approved as a drug for any use. It is studied in animal and early human research on metabolism and exercise physiology, not an approved medication.
Is MOTS-c legal in 2026? MOTS-c is not illegal to research, but it remains classified as Category 2, meaning 503A pharmacies cannot legally compound it into a prescription right now.
Why is MOTS-c still Category 2? An April 2026 HHS action moved 12 other peptides out of Category 2, but MOTS-c was not included. It remains under FDA review pending a future Federal Register notice.
What is MOTS-c studied for? MOTS-c is a mitochondrial-derived peptide, encoded in mitochondrial DNA. Early research links it to metabolic regulation and exercise-related signaling, mostly in animal models.
Disclaimer
As of July 2026, several peptides discussed in this article — including MOTS-c — are classified by the FDA as Category 2, which means they are not currently available from 503A compounding pharmacies. A February 2026 HHS announcement proposed returning these peptides to Category 1 pending formal FDA Federal Register notice. This article is educational and is not medical advice. Halftime Health only prescribes through licensed clinicians in states where our partner physicians are credentialed.
Get updates
Halftime Health is launching soon. We'll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we'll email you when we're live.
Sources
- U.S. Food and Drug Administration, Bulk Drug Substances Nominated for Use in Compounding Under Section 503A: https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-nominated-use-compounding-under-section-503a-federal-food-drug-and-cosmetic-act
- Federal Register, U.S. Food and Drug Administration agency notices: https://www.federalregister.gov/agencies/food-and-drug-administration
- National Center for Biotechnology Information, PubMed search: MOTS-c mitochondrial-derived peptide: https://pubmed.ncbi.nlm.nih.gov/?term=MOTS-c+mitochondrial+derived+peptide
Frequently asked questions
Is MOTS-c FDA approved?
No. MOTS-c is not FDA-approved as a drug for any use. It is a mitochondrial-derived peptide studied mainly in animal and early human research on metabolism and exercise physiology, not an approved medication.
Is MOTS-c legal in 2026?
MOTS-c sits in a gray zone. It is not illegal to research, but it remains classified by the FDA as Category 2, which means 503A compounding pharmacies cannot legally prepare it into a prescription right now.
Why is MOTS-c still Category 2?
An April 2026 HHS action moved 12 other peptides out of Category 2, but MOTS-c was not on that list. It remains under FDA review pending a future Federal Register notice, alongside compounds like BPC-157 and TB-500.
What is MOTS-c studied for?
MOTS-c is studied as a mitochondrial-derived peptide, meaning it is encoded in mitochondrial DNA rather than the cell's main genome. Early research links it to metabolic regulation and exercise-related signaling, mostly in animal models.
Keep reading
A licensed physician can build a protocol from your own labs.
Membership from $69/mo, including your onboarding panel. Each protocol is its own monthly subscription.